Form 8-K - Current report:
SEC Accession No. 0001708599-25-000055
Filing Date
2025-05-08
Accepted
2025-05-08 16:12:25
Documents
14
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ser-20250508.htm   iXBRL 8-K 24870
2 EX-99.1 ser-20250508xex991_earning.htm EX-99.1 121056
  Complete submission text file 0001708599-25-000055.txt   366935

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ser-20250508.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ser-20250508_lab.xml EX-101.LAB 54435
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ser-20250508_pre.xml EX-101.PRE 31811
16 EXTRACTED XBRL INSTANCE DOCUMENT ser-20250508_htm.xml XML 3014
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38519 | Film No.: 25926221
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)